CAB39 anticorps

N° du produit ABIN7239215

Détail du produit anti-CAB39 anticorps

Antigène: CAB39 (Calcium Binding Protein 39 (CAB39))

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CAB39 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Attributs du produit: Polyclonal Antibody

Purification: Affinity purification

Immunogène: Synthetic peptide of human CAB39

Isotype: IgG

Information d'application

Indications d'application: WB 1:500-1:2000, IHC 1:50-1:200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1.7 mg/mL

Buffer: PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Avoid freeze / thaw cycles.

Détails sur CAB39

Antigène: CAB39 (Calcium Binding Protein 39 (CAB39))

Autre désignation: CAB39 (CAB39 Produits)

Synonymes: anticorps CG4083, anticorps Dmel\\CG4083, anticorps Dmo25, anticorps dMo25, anticorps l(3)00274, anticorps mo25, anticorps fc06a03, anticorps zgc:86716, anticorps wu:fc06a03, anticorps MGC78903, anticorps CAB39, anticorps MO25, anticorps AA408805, anticorps AA960512, anticorps C78372, anticorps MO25alpha, anticorps CG4083 gene product from transcript CG4083-RA, anticorps calcium binding protein 39, anticorps calcium binding protein 39 L homeolog, anticorps Cab39 protein, anticorps Mo25, anticorps cab39, anticorps cab39.L, anticorps CAB39, anticorps Bm1_33380, anticorps Cab39

Sujet: Peutz-Jeghers Syndrome (PJS) is a rare hereditary disease characterized by melanocytic macules of the lips, gastrointestinal hamartomatous polyps and an increased risk for many classes of cancer. The serine/threonine kinase LKB1 (also designated STK11) has been identified as the gene mutated in PJS. LKB1 activity increases upon the binding of a regulatory complex consisting of the STE20-related adaptor-alpha (STRAD alpha) pseudo kinase and the calcium binding protein 39 (MO25 alpha). STRAD and MO25 determine the subcellular localization of LKB1 by initiating its translocation from the nucleus to the cytoplasm, thus regulating the tumor suppressor activity of LKB1. The LKB1/STRAD/MO25 complex acts as an AMP-activated protein kinase kinase (AMPKK).

Poids moléculaire: 40 kDa

NCBI Accession: NP_057373

UniProt: Q9Y376

Pathways: AMPK Signaling